Allurion Technologies (ALUR) Competitors $2.38 -0.03 (-1.04%) Closing price 03:58 PM EasternExtended Trading$2.38 0.00 (0.00%) As of 04:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALUR vs. TELA, LUNG, SPAI, CTSO, MDAI, SURG, SRTS, CTCX, RBOT, and INOShould you be buying Allurion Technologies stock or one of its competitors? The main competitors of Allurion Technologies include TELA Bio (TELA), Pulmonx (LUNG), Safe Pro Group (SPAI), Cytosorbents (CTSO), Spectral AI (MDAI), SurgePays (SURG), Sensus Healthcare (SRTS), Carmell (CTCX), Vicarious Surgical (RBOT), and Inovio Pharmaceuticals (INO). These companies are all part of the "medical equipment" industry. Allurion Technologies vs. Its Competitors TELA Bio Pulmonx Safe Pro Group Cytosorbents Spectral AI SurgePays Sensus Healthcare Carmell Vicarious Surgical Inovio Pharmaceuticals TELA Bio (NASDAQ:TELA) and Allurion Technologies (NYSE:ALUR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment. Do institutionals and insiders have more ownership in TELA or ALUR? 94.4% of TELA Bio shares are held by institutional investors. Comparatively, 21.4% of Allurion Technologies shares are held by institutional investors. 4.7% of TELA Bio shares are held by insiders. Comparatively, 9.6% of Allurion Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has stronger valuation & earnings, TELA or ALUR? Allurion Technologies has lower revenue, but higher earnings than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTELA Bio$69.30M0.97-$37.84M-$1.12-1.52Allurion Technologies$32.11M0.55-$26.15M-$12.50-0.19 Do analysts recommend TELA or ALUR? TELA Bio presently has a consensus price target of $4.50, suggesting a potential upside of 164.71%. Allurion Technologies has a consensus price target of $22.83, suggesting a potential upside of 861.40%. Given Allurion Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Allurion Technologies is more favorable than TELA Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TELA Bio 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Allurion Technologies 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.80 Which has more risk and volatility, TELA or ALUR? TELA Bio has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Comparatively, Allurion Technologies has a beta of -0.45, suggesting that its share price is 145% less volatile than the S&P 500. Does the media favor TELA or ALUR? In the previous week, Allurion Technologies had 8 more articles in the media than TELA Bio. MarketBeat recorded 16 mentions for Allurion Technologies and 8 mentions for TELA Bio. Allurion Technologies' average media sentiment score of 0.02 beat TELA Bio's score of -0.24 indicating that Allurion Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TELA Bio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Allurion Technologies 1 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is TELA or ALUR more profitable? TELA Bio has a net margin of -54.12% compared to Allurion Technologies' net margin of -86.05%. Allurion Technologies' return on equity of 0.00% beat TELA Bio's return on equity.Company Net Margins Return on Equity Return on Assets TELA Bio-54.12% -329.48% -57.34% Allurion Technologies -86.05%N/A -41.49% SummaryAllurion Technologies beats TELA Bio on 11 of the 17 factors compared between the two stocks. Get Allurion Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ALUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALUR vs. The Competition Export to ExcelMetricAllurion TechnologiesMED PRODUCTS IndustryMedical SectorNYSE ExchangeMarket Cap$17.72M$10.48B$5.70B$20.92BDividend YieldN/A1.90%3.77%3.59%P/E Ratio-0.1920.6730.8628.16Price / Sales0.5531.09403.8856.93Price / CashN/A24.9525.2217.81Price / Book-0.083.459.514.57Net Income-$26.15M$209.94M$3.26B$993.62M7 Day Performance-9.35%3.96%4.50%2.33%1 Month Performance-23.88%12.75%5.22%1.41%1 Year Performance-85.61%-9.39%31.92%13.75% Allurion Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALURAllurion Technologies2.5465 of 5 stars$2.38-1.0%$22.83+861.4%-85.4%$17.72M$32.11M-0.19501Analyst DowngradeShort Interest ↓Gap UpTELATELA Bio2.7352 of 5 stars$1.86+8.1%$7.25+289.8%-49.2%$68.04M$69.30M-1.32120Earnings ReportHigh Trading VolumeLUNGPulmonx4.2793 of 5 stars$1.55flat$7.66+394.5%-76.3%$63.16M$83.79M-1.08250SPAISafe Pro Group0.8221 of 5 stars$3.86-6.8%$8.00+107.3%N/A$62.81M$2.17M-4.7711Earnings ReportCTSOCytosorbents2.1401 of 5 stars$1.20+20.0%$5.50+358.3%+11.5%$62.76M$35.60M-7.06220Analyst RevisionGap UpMDAISpectral AI2.9827 of 5 stars$2.36-3.3%$3.50+48.3%+36.1%$61.77M$29.58M-4.3783News CoverageEarnings ReportAnalyst DowngradeAnalyst RevisionSURGSurgePays3.3674 of 5 stars$2.91-0.3%$9.00+209.3%+0.0%$59.60M$60.88M-1.0440Earnings ReportAnalyst DowngradeSRTSSensus Healthcare2.0796 of 5 stars$3.18-8.1%$9.33+193.5%-48.3%$56.98M$41.81M-53.0040High Trading VolumeCTCXCarmellN/A$2.70-4.6%N/A+166.7%$56.44M$32.84K0.0014Gap DownRBOTVicarious Surgical1.0532 of 5 stars$9.25-0.8%$8.50-8.1%+16.4%$55.27MN/A-0.89210Earnings ReportINOInovio Pharmaceuticals4.2191 of 5 stars$1.44+2.1%$8.80+511.1%-76.2%$51.71M$220K-0.45320Earnings ReportAnalyst DowngradeAnalyst RevisionGap Up Related Companies and Tools Related Companies TELA Bio Competitors Pulmonx Competitors Safe Pro Group Competitors Cytosorbents Competitors Spectral AI Competitors SurgePays Competitors Sensus Healthcare Competitors Carmell Competitors Vicarious Surgical Competitors Inovio Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ALUR) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allurion Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allurion Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access